文献速递鼻科

内镜鼻窦手术与度普利尤单抗治疗重度慢性鼻窦炎伴鼻息肉的前瞻性真实世界结局

Prospective Real-World Outcomes of Endoscopic Sinus Surgery and Dupilumab in Severe Chronic Rhinosinusitis With Nasal Polyps.
PubMed 文献 · Int Forum Allergy Rhinol · 2026-04-17

两种治疗均显著改善患者报告与客观结局且超过MCID;ESS早期改善更快,度普利尤单抗症状、嗅觉和鼻塞改善更持久,且急性加重和培养确诊细菌感染更少。

要点

  • ESS与度普利尤单抗均显著改善重度CRSwNP的SNOT-22、UPSIT-40、NCS和NPS,超过MCID。
  • ESS早期改善更快,度普利尤单抗在症状、嗅觉和鼻塞方面改善更持久。
  • 度普利尤单抗组急性加重和培养确诊细菌感染更少,无感染生存更长。

核心结论

  • ESS和度普利尤单抗对重度CRSwNP均带来有意义的获益,但时间反应模式不同。
  • 急性加重和细菌感染(尤其金黄色葡萄球菌)减少与更有利的疾病轨迹相关,提示个体化治疗选择中感染控制的重要性。

研究设计与样本

  • 患者经结构化共享决策接受ESS(n=30)或度普利尤单抗(n=20),随访12个月。
  • 基线和每3个月进行SNOT-22、UPSIT-40、NCS和NPS标准化评估,并通过双周症状调查前瞻性监测CRS急性加重。
  • 纵向结局采用混合效应模型分析,细菌性急性加重发生率采用回归和生存分析评估。

主要发现

  • 两种治疗均使患者报告和客观结局显著改善,超过最小临床重要差异。
  • ESS与更快的早期改善相关,而度普利尤单抗在症状、嗅觉和鼻塞方面显示更持久的改善。
  • 度普利尤单抗治疗患者CRS急性加重和培养确诊细菌感染发生更少,累积细菌负荷更低,无感染生存更长。
  • 金黄色葡萄球菌是最常见病原体,在ESS治疗患者中更频繁。
  • 细菌感染与持续更高的症状负担和更差的纵向结局相关。

关键数值与推荐

  • 所有患者符合EPOS诊断标准。
  • SNOT-22、UPSIT-40、NCS和NPS评估在基线和每3个月进行。
  • CRS急性加重通过双周症状调查监测,伴脓性分泌物时进行内镜培养。

临床怎么用

  • 重度CRSwNP治疗选择可结合ESS早期改善和度普利尤单抗持久改善及减少感染的特点进行共享决策。
  • 治疗中应关注急性加重和细菌感染(尤其金黄色葡萄球菌),感染控制可能改善长期结局。

局限性

  • 非随机分组,治疗分配基于共享决策,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease treated with endoscopic sinus surgery (ESS) or targeted biologic therapy such as dupilumab. Prospective real-world data guiding treatment decisions remain limited. MATERIALS AND METHODS: We conducted a single-center, prospective, real-world observational cohort study of adults with severe CRSwNP treated with ESS or dupilumab following structured shared decision-making. All patients met EPOS diagnostic criteria and were followed for 12 months. Standardized assessments were performed at baseline and every 3 months, including disease-specific quality of life (SNOT-22), olfaction (UPSIT-40), nasal congestion score (NCS), and endoscopic nasal polyp score (NPS). CRS exacerbations were prospectively monitored using biweekly symptom surveys, with endoscopic culture obtained during exacerbations with mucopurulence. Longitudinal outcomes were analyzed using mixed-effects models, and bacterial exacerbation incidence was evaluated using regression and survival analyses. RESULTS: Fifty adults completed 12-month follow-up (dupilumab, n = 20; ESS, n = 30). Both treatments resulted in significant improvements across patient-reported and objective outcomes, exceeding minimal clinically important differences. ESS was associated with more rapid early improvement, whereas dupilumab demonstrated more durable improvement in symptoms, olfaction, and nasal congestion. CRS exacerbations and culture-confirmed bacterial infections occurred less frequently in dupilumab-treated patients, with lower cumulative bacterial burden and longer infection-free survival. Staphylococcus aureus was the most common pathogen and more frequent among ESS-treated patients. Bacterial infection was associated with persistently higher symptom burden and worse longitudinal outcomes. CONCLUSIONS: ESS and dupilumab both provide meaningful benefit in severe CRSwNP, with distinct temporal response patterns. Reduced exacerbations and bacterial infections-particularly S. aureus-were associated with more favorable disease trajectories, underscoring the importance of infection control in individualized treatment selection.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Narendran N, Irish J, Samargandy S, et al. Prospective Real-World Outcomes of Endoscopic Sinus Surgery and Dupilumab in Severe Chronic Rhinosinusitis With Nasal Polyps. Int Forum Allergy Rhinol. 2026. PMID: 41995140. doi:10.1002/alr.70163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。